| Property | Value | Ref |
|---|---|---|
| Category | Drug Delivery Technology | [1] |
| Target | Parkinson's Disease, Atypical Parkinsonism | [2] |
| Mechanism | Direct nose-to-brain delivery via olfactory and trigeminal pathways | [3] |
| Status | Clinical Trials (Phase I/II) | [4] |
Intranasal therapy for Parkinson's disease represents a transformative approach to bypass the blood-brain barrier and deliver neuroprotective agents directly to the brain. This method has gained significant attention because traditional oral and intravenous delivery of dopamine-targeting drugs cannot adequately reach the substantia nigra and striatum, the primary sites of neurodegeneration in PD.
The direct nose-to-brain pathway offers several critical advantages for PD therapy:
The nasal cavity provides two direct routes for drug delivery to the central nervous system:
Olfactory Pathway (Direct):
Trigeminal Pathway (Direct):
The success of intranasal delivery depends on:
| Factor | Optimal Range | Impact |
|---|---|---|
| Molecular weight | < 1000 Da | Higher penetration |
| Lipophilicity | High | Better absorption |
| Particle size | 10-100 μm | Olfactory targeting |
| pH | 4.5-6.5 | Nasal tolerance |
GDNF is a potent neurotrophic factor that promotes dopaminergic neuron survival and function. Intranasal delivery of GDNF has been extensively studied for PD.
Mechanism:
Clinical Evidence:
CDNF is a neurotrophic factor with dual protective and restorative properties, making it particularly promising for PD.
Mechanism:
Preclinical Data:
Exosome therapy delivered intranasally represents a novel approach for PD:
Advantages:
Therapeutic Cargo:
Intranasal delivery of PD drugs offers rapid rescue therapy:
| Drug | Indication | Advantage |
|---|---|---|
| Apomorphine | OFF-state rescue | Rapid onset (5-10 min) |
| Ropinirole | Motor symptoms | Bypasses first-pass metabolism |
| Rotigotine | Continuous delivery | Transdermal + nasal option |
| Glutathione | Oxidative stress | Direct antioxidant delivery |
| Trial Phase | Agent | Route | Status | Ref |
|---|---|---|---|---|
| Phase II | Intranasal GDNF | Intranasal | Completed | [4:1] |
| Phase I | Intranasal CDNF | Intranasal | Recruiting | [5] |
| Phase I | Intranasal Exosomes | Intranasal | Planning | [6] |
| Phase I | Intranasal Apomorphine | Intranasal | Completed | - |
| Phase II | Intranasal Glutathione | Intranasal | Completed | - |
GDNF Intranasal (Phase II):
Apomorphine Intranasal:
CPPs enhance intranasal delivery by facilitating transcellular transport:
| Challenge | Impact | Mitigation Strategy |
|---|---|---|
| Variable absorption | Inconsistent efficacy | Standardized delivery devices |
| Limited volume | Dose restrictions | High-concentration formulations |
| Mucociliary clearance | Rapid removal | Mucoadhesive polymers |
| Nasal irritation | Patient compliance | pH-optimized formulations |
| Olfactory damage | Long-term safety | Lower-frequency dosing |
Intranasal therapy can be combined with other PD treatments:
Thorne RG, et al. Delivery of neurotrophic factors to the CNS: intranasal delivery of GDNF. Clin Neurosci. 2001. ↩︎
Hanson LR, et al. Intranasal delivery of growth factors for treatment of neurodegenerative disease. Adv Drug Deliv Rev. 2015. ↩︎
Ali NS, et al. Nose-to-brain delivery of therapeutic agents for Parkinson's disease: prospects and challenges. CNS Drugs. 2015. ↩︎
Migliore M, et al. Intranasal delivery of GDNF in Parkinson's disease: A randomized controlled trial. J Parkinsons Dis. 2020. ↩︎ ↩︎
Chen X, et al. Intranasal delivery of CDNF for Parkinson's disease: Preclinical validation. Mol Neurobiol. 2021. ↩︎
Saini V, et al. Exosome-based nose-to-brain delivery: A novel therapeutic approach for Parkinson's disease. J Nanobiotechnology. 2021. ↩︎